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Introduction
Fibrosis, or excessive collagen deposition that leads to permanent scar formation, is a common pathologic 
pathway in organ failure such as in renal fibrosis, cirrhosis, and chronic obstructive pulmonary disorder. 
Likewise, fibrosis of  the ocular mucosa (i.e., conjunctiva) is a clinically significant problem, which leads to 
blindness in advanced forms of  eye diseases, including trachoma, mucous membrane pemphigoid (MMP), 
and Stevens-Johnson syndrome. Fibrosis is also common in chronic allergic diseases (1–3), which include 
allergic bronchial asthma, atopic dermatitis, and atopic keratoconjunctivitis (4–6). The fibrogenic nature of  
allergic inflammation, including in allergic eye disease (AED), has been attributed to the Th2 lymphocyte 
cytokine IL-13 (1, 2, 5).
In addition, retinoic acid (RA) has received considerable attention in fibrosis pathobiology (7–10). 
Retinoid/vitamin A metabolites such as RA are important biological molecules involved in vision, devel-
opment, cell growth and maturation, apoptosis, and immunologic function. RA is also recognized for its 
role in fibroblast growth and proliferation and production of  extracellular matrix proteins such as colla-
gen (11–14). However, under certain pathologic settings, RA can exert profibrotic effects, as evidenced by 
hepatic stellar cells and liver fibrosis, as well as renal fibroblasts (7, 9, 10).
The emerging role in RA synthesis for DCs has been a topic of  intense investigation recently, with atten-
tion mostly focused on RA in immunologic homeostasis and lymphocyte homing within the small intes-
tine lamina propria and gut-associated lymphoid tissues (15–21). As a result, classical DCs (cDC) are now 
recognized as important producers of  the aldehyde dehydrogenase 1 (ALDH1) family. These enzymes are 
required in the oxidation step to convert retinal into all-trans-RA (ATRA) or isomerized 9-cis-RA (9-CisRA), 
which consequently signal to target cells in a paracrine manner through nuclear RA receptor (RAR) and 
retinoid x receptor (RXR) (22, 23). Recent reports also confirm the relevance of  RA synthesis by cDCs in 
other organs, such as the skin (24, 25). Furthermore, transcriptome data available through the Immunolog-
ical Genome Project Consortium (https://www.immgen.org/) corroborates that certain cDCs in liver and 
lung also express high levels of  Aldh1a2 mRNA (26), which may suggest that RA synthesis by nonlymphoid 
tissue cDCs is a generalized phenomenon.
Fibrosis is a shared end-stage pathway to lung, liver, and heart failure. In the ocular mucosa 
(conjunctiva), fibrosis leads to blindness in trachoma, pemphigoid, and allergy. The indirect 
fibrogenic role of DCs via T cell activation and inflammatory cell recruitment is well documented. 
However, here we demonstrate that DCs can directly induce fibrosis. In the mouse model of allergic 
eye disease (AED), classical CD11b+ DCs in the ocular mucosa showed increased activity of aldehyde 
dehydrogenase (ALDH), the enzyme required for retinoic acid synthesis. In vitro, CD11b+ DC–derived 
ALDH was associated with 9-cis-retinoic acid ligation to retinoid x receptor (RXR), which induced 
conjunctival fibroblast activation. In vivo, stimulating RXR led to rapid onset of ocular mucosal 
fibrosis, whereas inhibiting ALDH activity in DCs or selectively depleting DCs markedly reduced 
fibrosis. Collectively, these data reveal a profibrotic ALDH-dependent pathway by DCs and uncover a 
role for DC retinoid metabolism.
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Given the current understanding for cDC-derived ALDH in RA synthesis, in conjunction with the 
appreciable role of  RA on fibroblast function, we herein examined whether cDCs have a direct fibrogenic 
potential in the ocular mucosa by virtue of  ALDH produced by these cells. We took advantage of  the estab-
lished mouse model of  AED, which replicates sight-threatening allergies such as in atopic keratoconjunc-
tivitis and is often associated with conjunctival fibrosis (27). Our results reveal a particular subset of  cDCs 
(i.e., CD11b+ or cDC2) (28) with increased ALDH activity that causes ocular mucosal fibrosis in AED, and 
they implicate that this pathway is mediated via fibroblast RXR ligation of  RA. Importantly, we were able 
to demonstrate that selective depletion of  mouse DCs in vivo, or inhibition of  cDC-derived ALDH in vivo, 
led to the protection from fibrosis during AED. Our results are supported by the companion article by Dart 
and colleagues (29), who reveal a profibrotic autocrine mechanism mediated by fibroblast-derived ALDH 
in progressive scarring of  conjunctiva in patients with MMP — a prototypic human autoimmune mucosal 
scarring disorder.
In summary, results here demonstrate that cDC2-derived ALDH contributes to ocular mucosal fibro-
sis in allergic inflammation. Our findings are novel to our knowledge in that DCs are shown herein to 
induce fibrosis in a direct manner. Direct, cDC2-induced fibrosis is distinct from indirect fibrogenesis, 
which is mediated by activation or recruitment of  immune cells in chronic inflammation that in turn caus-
es fibrosis. We showed that DCs directly mediate fibrosis via RA synthesis. Indeed, both our study and the 
companion article converge on the finding that ALDH/RA plays a pivotal role in fibrosis of  the ocular 
mucosa. Thus, our work has the potential to open up a new area for fibrosis research in the cDC-mediated 
metabolism of  retinoids and the possibility for therapeutic strategies in combating fibrotic disease in eye 
and perhaps elsewhere. Future work is required to determine whether cDCs in humans likewise mediate 
fibrosis of  the ocular mucosa in allergy and whether our findings also extend to other fibrosis in other 
etiologies, such as trachoma.
Results
Uniquely high ALDH activity in steady-state cDC2s is conserved in multiple tissues. The ocular mucosa harbors 
steady-state cDC1 (i.e., CD103+) and cDC2 (i.e., CD11b+) (30), and our first aim was to measure these cells 
at the level of  the conjunctiva and draining submandibular/cervical lymph nodes (LNs) (Figure 1, A and B) 
for their ALDH activity. We also compared steady-state cDC1 and cDC2 from the lung as a control (Figure 
1C). Positive ALDH activity in these cells was determined using ALDEFLUOR staining, whereas negative 
controls for ALDH activity were accomplished by ALDEFLUOR staining in the presence of  the ALDH 
inhibitor diethylaminobenzaldehyde (DEAB). Data show that a large fraction of  cDC2 at all sites were 
ALDH+, whereas only a small fraction of  cDC1 were positive — and only at some sites (Figure 1, D and 
E). Furthermore, we were able to demonstrate that the transcriptome data available by Heng et al. from the 
Immunological Gene Network Consortium (26) show a similar trend for Aldh1a2 mRNA levels in CD11b+ 
cDCs from the lung, liver, and skin (Supplemental Figure 1; supplemental material available online with 
this article; doi:10.1172/jci.insight.87012DS1). Together, our findings led us to conclude that ALDH activ-
ity is uniquely high in ocular mucosal cDC2 and that this profile is conserved in multiple tissues.
ALDH activity from CD11b+ BM-derived DCs is fibrogenic via RA activation of  RXR in conjunctival fibroblasts. 
Based on our finding that cDC2s harbor uniquely high ALDH activity, we next wanted to investigate the 
potential effect of  cDC2-derived ALDH activity on fibrogenesis. To address this question, we took advan-
tage of  CD11b+ and CD103+ BM-derived DCs (BMDCs), which we generated with high yields using 
granulocyte-macrophage CSF (GM-CSF) and FMS-like tyrosine kinase 3 (Flt-3), respectively (25, 30, 31). 
Similar to Helft et al. (32), GM-CSF generated BMDCs resulted in a large fraction of  I-A/I-E bright cells 
and a smaller fraction of  I-A/I-E intermediate cells (Supplemental Figure 2). We verified that, like cDC2s, 
CD11b+ BMDCs harbored high ALDH activity, while CD103+ BMDCs did not (Figure 2, A and B), as 
reported by Yokota et al. (25).
Next, we transferred conditioned media from these respective BMDCs into cultures of  primary 
conjunctival fibroblasts and subsequently assayed contractile and proliferative capacities of  these fibro-
blasts. Data show that, compared with untreated fibroblasts, those receiving CD11b+ BMDC-condi-
tioned media had significantly lower levels of  contraction and proliferation (Figure 2C). We considered 
reduced proliferation and contraction of  conjunctival fibroblasts to be indicative of  a profibrotic state in 
the conjunctiva as a result of  the findings in the companion study. In their study, the profibrotic pheno-
type, demonstrated by explanted ocular MMP fibroblasts in vitro, showed a significant increase in both 
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Figure 1. Uniquely high aldehyde dehydrogenase (ALDH) activity in steady-state type-2 clas-
sical DCs (cDC2) is conserved in multiple tissues. (A–C) Gating strategies for analyzing steady-
state cDC1 and cDC2 in ocular (Oc) mucosa, draining submandibular/cervical lymph node (LN), and 
lung from normal C57BL/6 mice (PMN, neutrophils; Eo, eosinophils; Mo/MF, classical monocytes 
and macrophages). (D and E) Comparison of ALDH activity in cDC1s and cDC2s. Cell suspensions 
were stained with ALDEFLUOR to assess ALDH activity. Negative controls are shown for the 
respective cDC2 populations, which were ALDEFLUOR-stained samples treated with the ALDH 
inhibitor diethylaminobenzaldehyde (DEAB). Data are representative of duplicate data points 
from 2 separate experiments on pooled conjunctiva from n = 10 mice. Lung data is representative 
of triplicate data points from 3 separate samples from n = 20 mice (error bars represent ±SEM, 
***P < 0.0005, ****P < 0.00005, 1-way ANOVA with Bonferroni correction). Each experiment was 
carried out at least twice.
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Figure 2. Fibrogenic role for CD11b+ BMDC-derived ALDH on ocular mucosal fibroblasts. (A and B) Uniquely high aldehyde dehydrogenase (ALDH) activity of 
CD11b+ (11b) BM-derived DCs (BMDC), relative to CD103+ (103) BMDCs. (C) CD11b+ BMDC-derived ALDH impairs normal fibroblast proliferation and contractility in 
vitro. Primary conjunctival fibroblasts were plated in media for the proliferation assay or a free-floating collagen matrix for the contractility assay. Added to the 
wells were complete media only, conditioned media from CD11b+ BMDCs treated with or without diethylaminobenzaldehyde (DEAB), or conditioned media from 
CD103+ BMDCs as indicated. Gel contraction and proliferation was measured 1 d later. (D) Retinoid x receptor (RXR) signaling is responsible for CD11b+ BMDC-de-
rived ALDH impairment of normal fibroblast contractility and proliferation. Fibroblasts were plated in the presence of CD11b+ BMDC-conditioned media or not and 
treated with RXR or retinoic acid receptor (RAR) inhibitor as indicated. (E) 9-cis-RA (9c) mediates RXR signaling that causes impairment of normal fibroblast con-
tractility and proliferation. Primary conjunctival fibroblasts were plated, and some samples received 9c or all-trans-RA (AT), in addition to RXR inhibitor as indicat-
ed. (F) RXR agonist, bexarotene (Bex), impairs normal fibroblast contractility and proliferation (Veh, vehicle). (G) Local administration of Bex in vivo induces ocular 
mucosal fibrosis. Subconjunctival injection of Bex (10 ng) was administered to one eye, whereas the vehicle control was injected into the fellow eye. Clinical images 
were obtained, and Masson’s trichrome–stained sections of the conjunctiva were assessed (white arrows indicate diseased eye; black arrows indicate subepithelial 
collagen deposition). Triplicate data points represent fibroblast data from 3 separate fibroblast cultures from 3 different mice (error bars represent ±SEM, ***P < 
0.0005, ****P < 0.00005, 1-way ANOVA with Bonferroni correction). In vivo data are representative of n = 5 mice. Each experiment was carried out at least twice.
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intra- and extracellular collagen production but lower levels of  contraction and proliferation compared 
with those of  normal controls. The central role of  ALDH in this modulatory effect was confirmed in 
our study by application of  conditioned media from DEAB-treated CD11b+ BMDCs, which prevented 
decreased fibroblast proliferation and contraction (Figure 2C). In addition, consistent with our finding 
that cDC1 have low-level ALDH activity, use of  CD103+ BMDC-conditioned media did not alter normal 
fibroblast proliferation and contraction levels (Figure 2C). Taken together, our data suggest a possible 
fibrogenic role for CD11b+ BMDC-derived ALDH on primary conjunctival fibroblasts.
To further characterize the mechanism by which CD11b+ BMDC-derived ALDH mediates fibrogen-
esis, we evaluated the role of  RAR and RXR on fibroblasts, i.e. nuclear receptors in RA signaling. We 
accomplished this aim by assessing the effect of  RAR or RXR inhibitors on primary conjunctival fibro-
blasts cultured in fibrogenic CD11b+ BMDC-conditioned media. Data show that such conditioned media 
were no longer fibrogenic in the presence of  RXR inhibitor, as fibroblast contraction and proliferation levels 
were normal (Figure 2D). This restorative effect was not observed with RAR inhibition (Figure 2D). These 
data suggest that CD11b+ BMDC-derived ALDH mediates fibrogenesis through RXR and thereby prompt-
ed us to next examine whether RXR ligands 9-CisRA or ATRA are likewise fibrogenic. Indeed, we found 
that addition of  9-CisRA to primary conjunctival fibroblasts led to decreased contraction and proliferation 
(Figure 2E), and this effect was abolished when 9-CisRA was added with RXR inhibitor (Figure 2E). In 
contrast, ATRA did not exhibit this effect (Figure 2E). We also asked whether agonizing RXR on primary 
conjunctival fibroblasts is likewise fibrogenic. Indeed, data show that the addition of  RXR agonist bexaro-
tene is fibrogenic, as reduced contraction and proliferation levels in fibroblasts were observed (Figure 2F). 
Thus, our data together suggest that ALDH from CD11b+ BMDCs mediates fibrogenesis via activation of  
RXR in conjunctival fibroblasts.
We further went on to assess the role of  this RXR agonist in vivo and did so via subconjunctival injec-
tion of  bexarotene (0.2 ng/μl) into one eye of  naive mice (i.e., ipsilateral eye) while the fellow (i.e., contra-
lateral) eye was given the vehicle control. Data showed that bexarotene indeed led to fibrosis, as indicated 
clinically and histologically (Figure 2G). The vehicle-treated control eye was unaffected (Figure 2G). Thus, 
our data indicate that RXR activation causes ocular mucosal fibrosis in vivo and also corroborate that 
reduced proliferation and contraction of  conjunctival fibroblasts in vitro reflects a profibrotic state.
Association of  ALDH activity by cDC2s with ocular mucosal fibrosis during allergic inflammation. The fibro-
genic properties of  ALDH activity produced by CD11b+ BMDCs prompted us to next ask whether these 
cells are also profibrotic in vivo in the ocular mucosa. We addressed this question by taking advantage of  an 
established mouse model of  AED (30, 33, 34), which involves systemic OVA immunization and followed 
2 weeks later with once/day OVA eye drop instillations for 7 consecutive challenge days. This model is 
relevant because the human form of  this condition (i.e., atopic keratoconjunctivitis) causes scarring of  the 
ocular mucosa (27). Similarly, we found that mice with AED indeed developed mucosal fibrosis, evidenced 
both clinically and histologically (Figure 3, A and B). Furthermore, confocal microscopy of  ocular mucosal 
whole-mounts revealed that fibrosis was concurrent with increased ALDH activity (Figure 3C) and that 
ALDH was colocalized with antigen presenting cells (I-A/I-E+) (Figure 3C).
These findings prompted us to examine the status of  ALDH activity in ocular mucosal cDC2s during 
AED, which we accomplished via flow cytometry (Figure 3, D and E). Tissues were harvested at baseline 
and then at 20 minutes and 6 hours after challenge on each day. Consistent with our observations in the 
steady state, cDC2 conferred the highest ALDH activity, both at the level of  the ocular mucosa and LN 
(Figure 3F). Just as striking, we observed that ALDH activity in these cells increased significantly on day 2 
(at 6 hours after challenge) and on day 3 (at 20 minutes and 6 hours after challenge) (Figure 3G). Compar-
atively, other myeloid cells showed lower levels of  ALDH activity, both in the ocular mucosa and draining 
LN (Supplemental Figure 3). Furthermore, enumeration of  cDC2 revealed that these cells increased in 
number, as well (Figure 3E). Thus, our data allowed us to conclude that an increase in the number of  
cDC2s occurs in AED and that their ALDH activity increases on a per-cell basis.
Local Inhibition of  cDC2-derived ALDH protects mice from ocular mucosal fibrosis during allergic inflammation. 
Based on our in vitro and in vivo data, we next sought to address whether cDC2-derived ALDH contributes 
to mucosal fibrosis in AED. Our approach was to treat AED mice topically with the ALDH inhibitor DEAB 
once per day in one eye, whereas the contralateral eye was instead treated with the vehicle (Figure 4A). In this 
way, the contralateral eye serves as an internal control. More importantly, secondary activation of T cells in the 
draining LN of the untreated/contralateral eye can occur, which in turn ought to permit these contralateral T 
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cells to induce AED equivalently in both eyes, as was demonstrated in Figure 4A. The cDC2s in DEAB-treated 
eyes showed significantly reduced ALDH activity, whereas the vehicle-treated/contralateral eye maintained 
normal levels (Figure 4B). Thus, unilateral DEAB administration inhibits cDC2-derived ALDH in the treated 
eye only, while both eyes experience equivalent and fulminant levels of allergic inflammation.
Figure 3. Development of ocular mucosal fibrosis during allergic eye disease (AED) is associated with augmented 
cDC2-derived ALDH activity. Mice were immunized with OVA/adjuvant and challenged topically once daily with an OVA 
instillation to induce AED. (A and B) Ocular mucosal fibrosis develops in AED (black arrows). Data from whole eyes sec-
tioned and stained with Masson’s trichrome are representative of n = 3 per group (inset shows fibrosis/opaque white 
lesion in AED, not seen in naive mice). (C–F) Ocular (Oc) mucosal type-2 classical DC (cDC2) confer increased aldehyde 
dehydrogenase (ALDH) activity in AED. (C) Whole mount immunofluorescence of the ocular mucosa is representative 
of n = 5 per group. (D and E) Ocular mucosa and draining lymph node (LN) in AED were collected for flow cytometry 
analysis. Representative flow cytometry plots are shown from tissues collected at 6 hr after challenge on day 3. (F) 
Quantitation was performed on tissues collected at 20 min (20) and 6 hr (6) after OVA challenge on days (d) 0 through 
3 to measure ALDH activity by flow cytometry. (G) Ocular mucosal cDC2 increase in number during AED. Flow cytometry 
was carried out for enumeration of cDCs. Data shown for the ocular mucosal cDCs are representative of duplicate data 
points from 2 separate experiments. Cell suspensions were pooled samples from n = 10 naive mice or n = 6 mice for 
each experiment (error bars represent ±SEM; *P < 0.05, **P < 0.005; 1-way ANOVA with Bonferroni correction). Each 
experiment was carried out at least twice.
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Figure 4. Local inhibition of cDC2-derived aldehyde dehydrogenase (ALDH) protects mice from ocular muco-
sal fibrosis during allergic inflammation. Mice induced with allergic eye disease (AED) were treated with topical 
diethylaminobenzaldehyde (DEAB) in one eye and vehicle control in the fellow/contralateral eye. (A and B) Equiva-
lent levels of allergic inflammation in AED is achieved in the setting of unilateral DEAB instillation (black arrows). 
Clinical image and scores are derived from n = 12 mice. (B) Unilateral DEAB instillation in AED leads to reduced 
ALDH activity in type-2 classical DC (cDC2), as compared with those from the vehicle-treated contralateral eye. Flow 
cytometry data are derived from triplicate data points of pooled conjunctiva from n = 12 mice. (C) Unilateral DEAB 
instillation during AED leads to reduced collagen deposition in the ocular mucosa of the treated eye (black arrows). 
Images represent n = 6 mice. (D and E) Unilateral DEAB instillation restores normal levels of proliferation, con-
tractility, collagen production, and α smooth muscle actin (α) of AED conjunctival fibroblasts from the treated eye. 
Fibroblast data are represented by triplicate data points from 3 separate fibroblast cultures from 3 different mice 
(error bars represent ±SEM; *P < 0.05, ****P < 0.00005; 1-way ANOVA with Bonferroni correction). Each experiment 
was carried out at least twice.
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Using this approach, we next looked at Masson’s trichrome staining and found that impairing conjunc-
tival cDC2-derived ALDH reduced subepithelial collagen deposition in the ocular mucosa during AED 
(Figure 4C). We also cultured primary conjunctival fibroblasts from DEAB- and vehicle-treated eyes from 
these mice. Data showed that, compared with vehicle-treated controls, fibroblasts from the DEAB-treated 
eyes were restored with normal levels of  contraction, proliferation, collagen production, and α smooth 
muscle actin (α-SMA) expression (Figure 4, D and E). Thus, our data suggested that cDC2-derived ALDH 
causes ocular mucosal fibrosis during allergic inflammation.
Local depletion of  ocular mucosal cDCs protects mice from developing fibrosis during allergic inflammation. Our 
finding that targeting cDC2-derived ALDH protects mice from ocular mucosal fibrosis in AED would 
therefore predict that the depletion of  cDCs ought to have a similar protective effect. To address this pos-
sibility, we took advantage of  CD11c-eGFP/DTR mice and deleted CD11c+ cells by topical application of  
diphtheria toxin (DTx) during AED. Similar to the previous experiment, DTx was administered only to the 
ipsilateral eye (on days –1, 3, and 5), while the contralateral eye received a vehicle as an internal control. In 
this way, secondary activation of  T cells can occur in the draining LN of  the untreated/contralateral eye, 
which in turn ought to permit these contralateral T cells to induce AED equivalently in both eyes. Indeed, 
AED levels developed equivalently in both eyes (Figure 5A). We also verified using intravital multiphoton 
microscopy in this setting that our approach only depleted DCs in the ipsilateral DTx-treated eye (Figure 
5B). Consistent with this finding, we found in the AED setting that the ipsilateral draining LN likewise 
had reduced migratory cDC2s (Figure 5B and Supplemental Figure 4). A reduction of  monocyte-derived 
(Mo-derived) DCs in the ipsilateral LN was also observed; however, lymphoid-resident cDCs were not 
affected (Figure 5B and Supplemental Figure 3).
Using this approach we found that DC depletion resulted in reduced subepithelial collagen deposition 
in the AED setting, whereas the contralateral control eye did not (Figure 5C). These data were corroborat-
ed using primary conjunctival fibroblasts from such DC-deficient eyes, as primary conjunctival fibroblasts 
were restored with normal levels of  contraction, proliferation, and collagen production (Figure 5D). Thus, 
our data together allowed us to conclude that depletion of  DCs reduces levels of  ocular mucosal fibrosis 
during allergic inflammation.
Discussion
We herein establish that cDC2s in mice mediate ocular mucosal fibrosis in allergic inflammation, which 
is the first demonstration that DCs directly contribute to fibrosis. Our findings add to previous studies that 
have associated DCs with fibrosis indirectly, i.e., via their recruitment/activation of  other profibrotic leuko-
cytes (1–3, 35). The latter is exemplified by elegant work from Connolly et al., who recently reported that 
DC production of  TNF-α governs hepatic inflammation that causes liver fibrosis in mice (36).
Additionally, Kitamura et al. associated DCs and inflammation with αvβ8-mediated activation of  
latent TGF-β by fibroblasts in pulmonary fibrosis (37). Although indeed important, these are examples of  
indirect pathways for DC-mediated fibrosis, whereas we have demonstrated that cDCs can mediate fibrosis 
directly in the ocular mucosa, via RA synthesis. We also definitively show it is the cDC2s that mediate this 
effect, and these cells do so through their ALDH activity, which is augmented in allergic inflammation. 
As our data suggest, fibrogenesis in this setting occurs via ligation of  RA by conjunctival fibroblast RXR.
Pursuit of  our investigation was followed by Dart and colleagues’ findings of  ALDH-mediated auto-
regulation of  a profibrotic phenotype in conjunctival fibroblasts from patients with MMP (29). Their results 
led us to ask whether cDC2s also had fibrogenic potential in the ocular mucosa, given our observations 
that these cDCs harbored significant ALDH activity in steady-state ocular mucosa and in draining LN. 
Interestingly, we also found a similar trend in steady-state cDC2s in the lung, as well as in CD11b+ BMDCs, 
reported also by Yokota et al. (25). Furthermore, our data agree with Guilliams et al., who demonstrated 
an increased frequency of  ALDH+ cells in dermal CD103– cDCs as compared with CD103+ counterparts 
(24). Likewise, we were able to demonstrate, with transcriptome data generated by Heng et al. of  the 
Immunological Genome Project Consortium, a similar trend with Aldh1a2 mRNA levels in CD11b+ vs. 
CD103+ cDCs from skin-draining LN (i.e., MHCIIhiLangerin–CD103–CD11b+ vs. MHCIIhiLangerin+C-
D103+CD11b– cDCs, respectively), liver and lung (CD103–CD11b+CD24+ vs. CD103+CD11b–), and medi-
astinal LN (26). Thus, it is tempting to hypothesize that high ALDH activity and associated fibrogenic 
potential may be a unique feature intrinsic to the cDC2 cluster (28), which may predict high ALDH activ-
ity in the recently described cDC2-commited progenitor (38). However, we show that lymphoid-resident 
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Figure 5. Local DC depletion protects CD11c-eGFP/DTR mice from developing ocular mucosal fibrosis during allergic inflammation. Ipsilateral diphtheria 
toxin (DTx) instillation was given topically (3.125 ng) on days –1, 3, and 5 of challenge, whereas the contralateral eye received PBS control. (A) Equivalent 
levels of allergic inflammation in allergic eye disease (AED) is achieved despite unilateral DTx instillation to CD11c-eGFP/DTR mice (black arrows). Clinical 
scores and enumeration of ocular mucosal eosinophils (Eos) and CD4+ T cells (flow cytometry) compared DTx-treated eyes vs. PBS-treated contralateral 
eyes on day 7. (B) Deletion efficacy of unilateral DTx instillation. Intravital multiphoton microscopy of DTx-treated eye and vehicle-treated contralateral 
eyes was carried out in AED mice to verify DC deletion in the DTx-treated eye (SHG, second harmonic generation). Lymph nodes (LNs) were collected for 
flow cytometry to verify deletion of ipsilateral migratory type-2 classical DCs (cDC2). Data is derived from triplicate data points from n = 5 mice. (C) Unilat-
eral DTx instillation during AED leads to reduced collagen deposition in the ocular mucosa of the treated eye (black arrows). Micrographs represent n = 5 
mice. (D) Unilateral DTx instillation restores normal levels of proliferation, contractility, and collagen production of AED conjunctival fibroblasts from the 
treated eye. Fibroblast data are represented by triplicate data points from 3 separate fibroblast cultures from 3 different mice (error bars represent ±SEM; 
**P < 0.005, ****P < 0.00005; 1-way ANOVA with Bonferroni correction). Each experiment was carried out at least twice.
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cDC2s in the submandibular/cervical LN do not appear to harbor ALDH activity. Also known to express 
high levels of  ALDH are cDC1s in the small intestine lamina propria. Thus, high ALDH activity in cDC2s 
cannot solely be an intrinsic quality of  their particular developmental lineage, but it ought to also be an 
effect of  certain tissue-specific factors.
We identified the likely mechanism by which cDC2-derived ALDH activity mediates ocular mucosal 
fibrosis. First, we demonstrated using primary conjunctival fibroblasts that ALDH produced by CD11b+ 
BMDCs is fibrogenic in vitro, since conditioned media from DEAB-treated CD11b+ BMDCs prevented 
this result. Second, and supportive of  this profibrotic role for CD11b+ BMDC-derived ALDH, we proved 
that addition of  9-CisRA caused the same fibrogenic effect. This finding is in agreement with Okuno et 
al., who observed a similar result of  adding 9-CisRA to rat hepatic stellar cells (7). Third, we demonstrat-
ed with agonist/antagonist experiments on primary conjunctival fibroblasts that RXR signaling mediates 
the observed fibrogenic effect in this system. These findings support our aforementioned observation that 
9-CisRA is fibrogenic, since this isomer is the high-affinity ligand of  RXR (22, 23). Importantly, we were 
able to show in vivo that agonizing RXR via bexarotene injection in vivo led to ocular mucosal fibrosis. 
Thus, our data collectively suggest that cDC2-derived ALDH plays a key role in consequent 9-CisRA syn-
thesis, which is fibrogenic to the ocular mucosa.
In vivo evidence that cDC2-derived ALDH activity is central to mediating ocular mucosal fibrosis 
in the AED setting was also obtained. We showed that the absolute numbers of  ocular mucosal cDC2s 
increase significantly in AED, which agrees with the same increase in CD11b+ cDCs reported by Plantinga 
et al. in the allergic airway inflammation setting (39). We also show that ocular mucosal cDC2s increase 
their ALDH activity significantly in AED, and thus one can surmise that both their increased ALDH activ-
ity and absolute numbers could result in enhanced levels of  profibrotic 9-CisRA in the AED. Of  note, in 
our study, no other myeloid population examined (e.g., Mos, eosinophils, macrophages, or PMN) showed 
persistent levels of  ALDH activity similar to that of  ocular mucosal cDC2s. Likewise, transcriptome data 
from Heng et al. corroborate low Aldh1a2 mRNA levels in granulocytes, Mos, and macrophages (except 
for peritoneal macrophages), as well as in lymphocytes and innate lymphoid cells (26), suggesting that high 
activity of  ALDH1 enzymes is not conserved across all immune cell types, as previously appreciated (19).
Our key in vivo findings came from experiments in which we were able to perturb cDCs in the AED 
setting. By taking advantage of  a similar technique shown by Gao et al. to deplete ocular DCs through local 
DTx administration in CD11c-eGFP/DTR mice (40), we were able to demonstrate that DC depletion in the 
ocular mucosa resulted in significantly reduced levels of  fibrosis in the AED setting. Interestingly, Jiao et 
al. recently reported that DCs and plasmacytoid DCs (pDCs) contribute to regression of  liver fibrosis in the 
carbon-tetrachloride model and that systemic DTx administration in CD11c-eGFP/DTR mice led to a delay 
in this regression (41). In our study, we further verified the contribution of  cDC2-derived ALDH activity 
in ocular mucosal fibrosis via topical administration of  DEAB, which led to significantly reduced levels of  
fibrosis during AED. Thus, consistent with our in vitro findings, our data collectively suggest that ALDH 
activity from cDC2s is responsible for ocular mucosal fibrosis during AED.
Importantly, this in vivo approach in testing the role of  cDC2-derived ALDH was carefully devised so 
as to manipulate DCs without reducing allergic inflammation. Uncoupling inflammation and fibrosis is 
particularly important when studying RA, as retinoids can suppress fibrogenic inflammation (7, 19, 24, 42). 
In the allergy setting, DCs trigger secondary Th2 responses that perpetuate allergic inflammation, as well; 
therefore, reducing T cell responses could also lessen fibrogenic inflammation (1–3, 35). Thus, to study 
ocular mucosal fibrosis while maintaining fulminant allergic inflammation levels, we induced AED in both 
eyes but only manipulated ocular mucosal cDCs unilaterally. In this way, the control eye would drive full 
development of  secondary Th2 responses systemically to elicit fulminant AED in both eyes. The data sup-
ported our hypothesis, since ipsilateral DEAB treatment in one series of  experiments and ipsilateral DTx 
treatment in the other experiments resulted in equivalent AED and cellular recruitment levels in both eyes. 
Thus, we were able to dissect out the direct fibrogenic role of  cDC2-derived ALDH in the AED setting.
The studies described in the accompanying paper, from Dart and colleagues, and our work here, both 
converge on the finding that ALDH/RA plays a central role in ocular mucosal fibrosis in mice and humans 
(29). Their study provides evidence that the ALDH/RA pathway is critical in conjunctival fibrosis seen in 
MMP patients and further shows, in the same AED mouse model used here, that conjunctival scarring also 
develops . Sensitized mouse conjunctival fibroblasts were demonstrated in their study to behave identically 
to human diseased fibroblasts in vitro, with respect to their profibrotic profile and restoration of  normal 
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functionality by in vivo topical application of  ALDH inhibitor disulfiram during AED. Our work demon-
strates a paracrine profibrotic effect of  ALDH/RA on conjunctival fibroblasts produced by cDC2s in AED 
and may suggest a similar role for the human CD1c+ cDC homologue (reviewed in ref. 43), whereas Dart 
and colleagues’ work highlights an autocrine profibrotic mechanism in ALDH/RA by conjunctival fibro-
blasts in human ocular MMP and in mouse AED (29). Their conclusion in human MMP was supported 
by upregulated ALDH found in conjunctival fibroblasts from these patients and by the fact that these fibro-
blasts maintain a range of  profibrotic characteristics in vitro that are restored to normal by application of  
ALDH inhibitors. Thus, their findings identify this pathway as an underlying mechanism in the previously 
unknown pathogenesis of  progressive conjunctival scarring.
In summary, we herein demonstrate that cDC2s are inducers of  ocular mucosal fibrosis in the allergic 
setting, which is the first in vivo demonstration that DCs can directly effect fibrosis. Work in the companion 
study shows ALDH-mediated autoregulation of  a profibrotic phenotype in conjunctival fibroblasts from 
patients with MMP (29). We show that uniquely high ALDH activity of  cDC2s is fibrogenic in allergic 
inflammation, which our data suggest leads to ligation of  9-CisRA by RXR on conjunctival fibroblasts. Our 
findings not only have the potential to open up a novel area for fibrosis research in cDC-mediated retinoid 
metabolism, but also advance the current understanding of  the DC-RA axis beyond its already appreciated 
role in T cell homing and tolerance. Future work is required to determine whether cDCs in humans like-
wise mediate fibrosis of  the ocular mucosa in allergy and whether our findings also extend to other fibrosis 
in other etiologies, such as trachoma.
Methods
Animals and euthanasia. Female C57BL/6 (B6) mice aged 8–12 weeks were purchased from Charles Riv-
er Laboratories. CD11c-eGFP/DTR mice also 8–12 weeks were gifted from the labs of  Soman Abraham 
(Department of  Pathology, Duke University) and Mari Shinohara (Department of  Immunology, Duke Uni-
versity), which were originally purchased from Jackson Laboratory (stock no. 004509). Mice were housed 
in a specific pathogen-free environment at the Duke Eye Center animal facility. Anesthesia was used for all 
surgical procedures with i.p.-administered ketamine/xylazine suspensions (120 and 20 mg/kg, respectively).
AED. AED was induced in 9–12 week old WT B6 mice, as previously described (30, 33, 34). Briefly, 
one i.p. administration of  ovalbumin (OVA; 50 ng/μl, Sigma-Aldrich) emulsified in aluminium hydroxide 
(2 μg/μl, Thermo Scientific) and pertussis toxin (1.5 ng/μl, Sigma-Aldrich), in a total volume of  200 μl of  
sterile saline. Two weeks later, mice received a daily eye drop instillation of  5 μl OVA (50 μg/μl) in sterile 
saline for 7 days. Clinical parameters including eyelid edema, chemosis, conjunctival redness, and tearing 
were each scored on a scale of  0–3+, as previously described (30, 33, 34).
BMDCs. BMDCs were generated as previously described (25, 30, 31, 33, 34). Briefly, femurs and tibiae 
were collected from freshly euthanized B6 mice, BM harvested, and single cell seeded at 2 × 105/ml. RPMI 
1640 (Lonza) was supplemented with 10% FBS and 1% penicillin/streptomycin, plus 20 ng/ml mouse 
GM-CSF (all from BioLegend). For generation of  CD103+ BMDCs, Flt-3 (100 ng/ml, eBioscience) was 
used instead of  GM-CSF. On day 4, fresh GM-CSF (20 ng/ml) was added to both culture conditions.
Primary conjunctival fibroblasts. Primary conjunctival fibroblasts were expanded from whole conjunctival 
tissue explants excised from freshly euthanized B6 mice and placed under a glass coverslip with RPMI 1640 
supplemented with 10% FBS and 1% penicillin/streptomycin. Fibroblasts between passages 4–6 were uti-
lized in the assays described below.
Fibroblast collagen production assay in vitro. Fibroblasts were seeded at 3 × 104 cells per well on a 24-well 
plate for 24 hours. Collagen solubilization was carried out first with cell lysis using 0.05 M acetic acid 
(Sigma-Aldrich) followed by a 2-step digestion using pepsin (0.1 mg/ml; Sigma-Aldrich) and pancreatic 
elastase (0.1 mg/ml; Sigma-Aldrich). Collagen was solubilized and measured using mouse collagen type 1 
ELISA according to the manufacturer’s protocol.
Fibroblast matrix contraction assay in vitro. Fibroblasts were plated at a density of  1.6 × 106 cells/ml with 
10× concentrated MEM (Invitrogen) and collagen type 1 solution (2 mg/ml, First Link) in a final volume 
of  1 ml. The collagen stock solution contains 0.6% acetic acid and was neutralized with 5 M NaOH (Sig-
ma-Aldrich) prior to addition of  cells. The collagen/fibroblast mixture (60 μl per well of  a 96-well plate) 
was left to set at 37˚C for 30 minutes in 5% CO2 in air. RPMI 1640 supplemented with 10% FBS, and 1% 
penicillin/streptomycin was added to the gels before they were released from the well edge. Gels were incu-
bated at 37˚C in a humidified atmosphere of  5% CO2 in air. Images were captured on day 1 with a standard 
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digital camera. Gel areas were measured and analyzed using Image J software (NIH).
Fibroblast proliferation assay in vitro. Fibroblasts/ml (5 × 104 ) in a total volume of  100 μl were seeded in a 
96-well plate, and proliferation was determined using the CyQuant proliferation kit (Invitrogen) as per the 
manufacturers’ protocol.
Manipulation of  RA pathway in fibroblasts in vitro. RA (9-CisRA and ATRA) (Sigma-Aldrich), RXR inhib-
itor HX531, and RAR inhibitor BMS 195614 (both from Tocris) were dissolved in 100% DMSO (Sigma-Al-
drich). They were then diluted in a sterile saline to a final concentration of  10 μM (final DMSO content 
of  0.01%). These solutions were added to fibroblast assays 24 hours before day-1 readings in each assay.
Fibroblast α-SMA expression. Expression of  fibroblast α-SMA was assessed by confocal microscopy of  
fibroblasts in tethered collagen type 1 gels. The gels were formed similarly to the free-floating gels in the 
contraction assay; however, the gels were not released from the edges of  the well. After 24 hours, the gels 
were stained with α-SMA antibody (Cy3 conjugated, Sigma-Aldrich) using the staining protocol recom-
mended by the manufacturer. Confocal microscopy was carried out using the Leica SP5 (Leica Microsys-
tems) followed by image analysis with Leica LAS AF lite software.
Bexarotene use in vivo and in vitro. Bexarotene (B-2422 Free Acid > 99%, LC Laboratories) was initially 
dissolved in 50% ethanol solution at pH of  13 and then neutralized to a pH of  7.5 with 100% ethanol 
solution at a pH of  2. The final working concentration of  bexarotene was 0.2 μg/ml, leading to a 0.3% eth-
anol vehicle. Subconjunctival injection were performed as previously described (30) and used to administer 
bexarotene (0.2 μg/ml, 50 μl) or ethanol vehicle (0.3%, 50 μl) into to naive B6 mice. For the in vitro assay, 
bexarotene (0.075 μg/ml, 0.1% ethanol vehicle) was added to fibroblasts.
DEAB use in vivo and in vitro use. DEAB powder (Sigma-Aldrich) was dissolved in 100% DMSO (Sig-
ma-Aldrich) and subsequently diluted in sterile saline to a final concentration of  300 μM. DEAB was 
applied topically to one eye of  mice with AED, and vehicle (0.03% DMSO in sterile saline) was applied 
to the contralateral eye once a day, 1 hour prior to challenge. For in vitro assays, DEAB (100 μM, 0.01% 
DMSO in sterile saline) was added to the BMDC cultures prior to BMDC conditioned-media being applied 
to fibroblast assays.
DTx preparation and administration. AED was induced in CD11c-DTR/GFP mice. Twenty-four hours 
prior to day 1 of  OVA challenge, and on days 3 and 5, DTx (3.125 ng, 5μl) was added topically to the ocular 
surface of  the ipsilateral eye while the contralateral eye received a sterile saline (5 μl) vehicle. The DTx and 
vehicle were left on the ocular surface for 1 minute and then washed 4 times with sterile saline. Multiphoton 
microscopy was utilized to visualize the GFP signal in each eye of  live mice on days 1 and 7 of  challenge.
Collagenase tissue digestion. Tissues were minced and digested in 2 mg/ml collagenase D (Roche Diag-
nostics) and 0.05 mg/ml DNase (Roche Diagnostics) for 45 minutes at room temperature using the Gentle-
MACS Dissociator (Miltenyi Biotec). Cell suspensions were triturated in 20 mM EDTA, passed through a 
70-μm filter (BD Falcon; BD Biosciences), and thoroughly washed.
Flow cytometry. The following antibodies or dyes were used for flow cytometry: Viability (65-0863-14, 
eBioscience), ALDH/ALDEFLUOR (01700, Stem Cell Technologies), F4/80 (BM8, eBioscience), CD103 
(2E7, BioLegend), Ly6C (AL-21, BD Pharmingen), Ly6G (1A8, BioLegend), CD64 (X54-5/7.1, BioLeg-
end), I-A/I-E (M5/114.15.2, BioLegend), CD11b (M1/70, BD Pharmingen), CD11c (HL3, BD Pharmin-
gen), CD45 (30-F11, eBioscience), Siglec-F (E50-2440, BD Pharmingen), CD8 (53-6.7, BioLegend), CD3 
(17A2, BioLegend), and B220 (RA3-6B2, BioLegend). Data acquired on BD Fortessa LSRII and analyzed 
on FloJo (Treestar Inc.)
ALDEFLUOR. Cell suspensions were treated with ALDEFLUOR (Stem cell Technologies) as per man-
ufacturer’s instructions. Briefly, 5 μl of  the activated ALDEFLUOR was added to the cell suspensions and 
then incubated in the dark at 37°C for 30 minutes. The samples were washed and resuspended in ALDE-
FLUOR buffer. Parallel aliquots of  DEAB-treated ALDEFLUOR-stained cell suspensions from each sam-
ple were included to confirm ALDH activity.
Histopathology. Whole eyes were obtained from freshly euthanized mice, stored in 10% formalin, pro-
cessed by the standard methods, and embedded in paraffin. Sections (5-μm) were processed and stained 
with Martius Scarlet Blue Stain (MSB) and H&E (Pathology Core Laboratories). Images of  the bulbar 
conjunctiva were taken using the Olympus Inverted Microscope CKX41 and Infinity1-2CB/2MP Digital 
Color Camera (Olympus America Inc).
Immunofluorescence microscopy. Conjunctival tissues excised from mice were fixed in 4% (v/v) parafor-
maldehyde (PFA, Sigma-Aldrich) for 1.5 hours and thoroughly washed. The samples were then blocked 
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with 5% goat serum (Sigma-Aldrich) for 30 minutes and subsequently stained with rabbit anti-mouse 
ALDH1 (Abcam) and rat anti-mouse MHC-II (eBioscience) primary antibody in 5% (v/v) goat serum 
(Invitrogen) for 48 hours at 4˚C in the dark. Samples were thoroughly washed and stained with goat 
anti-rabbit Alexa fluor 633 (Invitrogen) and goat anti-rat Alexa fluor 488 (Invitrogen) secondary antibody 
in 5% (v/v) goat serum and incubated for 1 hour at room temperature. Samples were thoroughly washed 
and mounted with DAPI-containing media (Vector Laboratories). Images were captured using a Leica SP5 
(Leica Microsystems), followed by image analysis with Leica LAS AF lite software.
Statistics. Experiments conducted in vivo were carried out on groups of  mice containing n = 5 mice, 
or as specified in the figure legends. The experiments that were carried out in vitro were conducted on 
cultures explanted from at least 3 separate mice. Overall, experiments were carried out on at least 2 sepa-
rate occasions. Box and whisker plots use the standard method (Prism, GraphPad). Specifically, whiskers 
indicate the min and max, the hinges indicate the 25th to 75th percentiles, and the middle line is plotted at 
the median. For statistical analysis, the 1-way ANOVA was used with Bonferroni correction to obtain SEM 
and statistical significance. A P value of  less than 0.05 was considered significant.
Study approval. Duke Institutional Animal Care and Use Committee approved all animal procedures. 
All animals were treated according to the ARVO Statement for the Use of  Animals in Ophthalmic and 
Vision Research, NIH guidelines on the care and use of  animals, and the American Veterinary Medical 
Association (AVMA) Panel on Euthanasia.
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